George Uy founded TRIGR in April 2018 with over 35 years of pharmaceutical and biotech leadership experience. For over 20 years, George was principally responsible for leading strategic marketing and commercial initiatives across Roche (Manila, Basel and Nutley) including establishing Roche Shanghai Commercial and launching Xeloda® in oncology in the USA . Subsequent to his tenure at Roche, George joined Abraxis Biosciences (formerly Nasdaq: ABRX now CELGENE) where he helped built out the oncology commercial organization and was responsible for all aspect of the launch from pre-marketing to commercialization of Abraxane®. George then served as Senior Vice President of Commercial Operations at Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPM) and most recently, as Chief Commercial Officer Sorrento Therapeutics (Nasdaq: SRNE), where he was instrumental in transitioning the Company from the OTC market to Nasdaq. George holds a Bachelor of Science in Medical Technology from the Cebu Institute of Medicine, Philippines.
Ms. Toledano joined TRIGR in 2018 with over 20 years of biotech related Wall Street principal investment, capital market and advisory experience. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) as EVP Corporate Development where she helped drive the Company’s hematology/oncology (IO mAbs, ADC), cellular therapy (CD-38 CAR-T, oncolytic virus) and pain franchises. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she was completed biotech equity financings (IPO, follow-on) totaling over $4 billion in aggregate value. Prior to joining MLV, from 2004 until 2010, Ms. Toledano served as a VP in the investment group of Royalty Pharma, where she focused on oncology/hematology and auto-immune monoclonal antibody investments. From 1998 to 2003, Ms. Toledano led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
Young-Jin Kim is Chairman & CEO of Handok Inc. (KRX:002390), one of the leading pharmaceutical companies in Korea. Handok, which originated as a joint venture with Hoechst AG in Germany in 1964, Aventis in 2000, and Sanofi in 2005, has been operating as an independent entity since 2012.
Chairman Kim joined Handok in 1984, serving in several senior capacities within the framework of Hoechst AG Korea and Aventis Pharma Korea. In 1996, Young-Jin Kim was appointed CEO of Handok and has been leading the Company in its expansion for over 20 years. Under Chairman Kim’s leadership, Handok consolidated into an independent entity by acquiring Sanofi Aventis’ stake in the JV in 2012.
Chairman Kim has been serving as the President of KDG (Korean-German Society) since 2010. He also served as the Vice Chairman of the Korean Pharmaceutical Manufacturers Association and the 5th Chairman of KGCCI (Korean-German Chamber of Commerce and Industry). Since 2014, he also has been serving as the President of the Handok Jeoseok Foundation. Young-Jin Kim received his MBA degree at the Kelley School of Business at Indiana University in 1984 and received the award of Distinguished Alumni Fellows from Indiana University. He completed his Advanced Management Program (AMP) at the Harvard Business School in 1996.